Drug profile · INN
dextromethorphan hydrobromide
NUEDEXTA
dextromethorphan hydrobromide (NUEDEXTA) is a glutamate [nmda] receptor subunit epsilon 1 antagonist. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — dextromethorphan hydrobromide
- US status
- approved
- Class
- Nervous system (N07)
- Route
- ORAL
- Patents
- 16
- Programs
- 1
- Data quality
- 0.89
Quick answer
dextromethorphan hydrobromide (NUEDEXTA) is a glutamate [nmda] receptor subunit epsilon 1 antagonist. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Glutamate [NMDA] receptor subunit epsilon 1 antagonist
Primary target: Glutamate receptor ionotropic, NMDA 2A
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | withdrawn | — |
Pipeline programs
Related & competitor drugs
Related patents
-
US 12357697
Pharmaceutical compositions comprising bupropion and cysteine
granted -
US 12156914
Pharmaceutical compositions comprising bupropion and cysteine
granted -
US 12077549
Pentaaza macrocyclic ring complexes possessing oral bioavailability
granted -
US 11612608
Methods of treating oral mucositis
granted -
US 11129826
Bupropion as a modulator of drug activity
granted -
US 11123344
Bupropion as a modulator of drug activity
granted -
US 11066433
Pentaaza macrocyclic ring complexes possessing oral bioavailability
granted -
US 10610533
Methods of treating oral mucositis
granted -
US 10597415
Pentaaza macrocyclic ring complexes possessing oral bioavailability
granted -
US 10350193
Super-oxide dismutase mimetics
granted -
US 9855279
Methods of treating oral mucositis
granted -
US 9738669
Pentaaza macrocyclic ring complexes possessing oral bioavailability
granted -
US 9738670
Pentaaza macrocyclic ring complexes possessing oral bioavailability
granted -
US 9642861
Methods of treating oral mucositis
granted -
US 9353069
Super-oxide dismutase mimetics
granted -
US 8486928
Super-oxide dismutase mimetics
granted
Frequently asked questions
What is dextromethorphan hydrobromide?
dextromethorphan hydrobromide (NUEDEXTA) is a glutamate [nmda] receptor subunit epsilon 1 antagonist. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for dextromethorphan hydrobromide?
NUEDEXTA is a marketed brand name for dextromethorphan hydrobromide. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of dextromethorphan hydrobromide?
dextromethorphan hydrobromide has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.